Q32 Bio was founded by Shelia Violette, Michael Holers in 2017.

Who are Q32 Bio's investors?

Q32 Bio's investors include Atlas Venture, OrbiMed, Agent Capital, CU Healthcare Innovation Fund, OUP (Osage University Partners), Sanofi Ventures, 5AM Ventures, ACORN BIOVENTURES and 1 more.

How much funding has Q32 Bio raised?

Q32 Bio has disclosed $10M raised across 1 of its 4 known rounds.

Q32 Bio

NASDAQ: QTTB

Founded 2017 · 30 employees on LinkedIn · 9 known investors

Find your way into Q32 Bio

Each arrow is one introduction. Sign up to fill in the first one.

265 people can intro you to Shelia

Ask Patrick Lucy to introduce you to Shelia Violette

You →Patrick · together at Repligen Corporation →Shelia

221 people can intro you to Jodie

Ask Jamie Chen to introduce you to Jodie Morrison

You →Jamie · together at Verve Therapeutics →Jodie

121 people can intro you to David

Ask Sam Okafor to introduce you to David Appugliese

You →Sam · together at Q32 Bio →David

Your email: who you already know at Q32 Bio, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Q32 Bio team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis. The company was formed through a merger with Homology Medicines in 2024 and is led by a team with immunology and biopharmaceutical drug development experience.

Biotech Healthtech

Founders & leadership

Q32 Bio was founded in 2017 by Shelia Violette and Michael Holers.

Shelia Violette Founder & Chief Scientific OfficerShelia Violette is Founder and Chief Scientific Officer of Q32 Bio, a biotechnology company developing therapies for autoimmune and inflammatory diseases. She has extensive experience in translational research and clinical drug development, particularly in inflammation, autoimmunity, and fibrosis.

Michael HolersCo-founder

Jodie Morrison Chief Executive OfficerJodie Morrison is Chief Executive Officer of Q32 Bio, a biotechnology company developing therapies for autoimmune and inflammatory diseases. She brings experience as an executive and board member in the biotechnology industry.

Lee KalowskiPresident & Chief Financial Officer

Maria MarzilliChief Business Officer

David Appugliese Senior Vice President, Head of PeopleDavid Appugliese is Senior Vice President of People at Q32 Bio, a biotechnology company developing therapies for autoimmune and inflammatory diseases. He has held leadership roles in both Fortune 500 companies and early-stage startups, including experience guiding companies through IPO.

Investors · 9

Atlas Venture✓ confirmed by Q32 BioCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · the company's own site · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

OrbiMed✓ confirmed by Q32 BioNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the company's own site · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Agent Capitallisted by Agent CapitalWaltham

How we know: Agent Capital's portfolio page · the VCSheet dataset · Not right? Tell us

CU Healthcare Innovation Fundlisted by CU Healthcare Innovation FundAurora

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

5AM VenturesreportedSan Francisco · $100K – $4M

How we know: the S-1 prospectus · Not right? Tell us

ACORN BIOVENTURESreportedNew York

How we know: a partner's Signal profile · Not right? Tell us

Vivo PandareportedPalo Alto

How we know: the S-1 prospectus · Not right? Tell us

Valuation · disclosed

Disclosed events

$577.3Mvaluation at IPOMar 2018 · $16.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

3 people who came through Q32 Bio went on to found or lead other companies.

Simon ReadScientific Advisory Board MemberFounded Mariana Oncology +2 MARK IWICKIBoard ChairFounded Inhibikase Therapeutics +2 Kathryn GoldenVice President CMCFounded Sunflower TX

Related companies · 6

StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Q Bio, Inc.Q.bio provides quantitative biology assessments and longitudinal health monitoring for preventive care, offering comprehensive measurable exams at the scale of premium care providers.

Qu BiologicsQu Biologics develops treatments aimed at cancer, chronic inflammatory diseases, and metabolic diseases by restoring normal immune function. It operates in the biotech and immunotherapy space.

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies working in the same space as Q32 Bio.

In the news

Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant dealstocktitan.net · Jul 2026

Frequently asked questions

What does Q32 Bio do?: Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis. The company was formed through a merger with Homology Medicines in 2024 and is led by a team with immunology and biopharmaceutical drug development experience.
Who founded Q32 Bio?: Q32 Bio was founded by Shelia Violette, Michael Holers in 2017.
Who are Q32 Bio's investors?: Q32 Bio's investors include Atlas Venture, OrbiMed, Agent Capital, CU Healthcare Innovation Fund, OUP (Osage University Partners), Sanofi Ventures, 5AM Ventures, ACORN BIOVENTURES and 1 more.
How much funding has Q32 Bio raised?: Q32 Bio has disclosed $10M raised across 1 of its 4 known rounds.